FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
The month ahead: July’s upcoming events
Regeneron is facing two FDA decisions for its T-cell engagers.
Astra looks to confirm Datroway's turnaround
The Avanzar study could read out shortly.
Deals accompany new phase 1 trial starts
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
TuHura makes its bid for Merkel accelerated approval
The company reckons its immunotherapy could improve on Keytruda.
After Blueprint's takeover comes Cogent's big test
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
Arvinas and 3SBio hope to do better
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
